PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Texas Instruments Incorporated (TXN)
205.980.01 (0.00%)
205.24 - 207.41
139.95 - 221.69
4.54M / 6.54M (Avg.)
37.59 | 5.48
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
-14.51%
Negative net income growth while AVGO stands at 9.27%. Joel Greenblatt would see a comparative disadvantage in bottom-line performance.
0.38%
Some D&A expansion while AVGO is negative at -0.08%. John Neff would see competitor’s short-term profit advantage unless expansions here deliver big returns.
-5666.67%
Both lines show negative yoy. Martin Whitman would see an industry or cyclical factor reducing tax deferrals for both players.
-8.82%
Negative yoy SBC while AVGO is 3.75%. Joel Greenblatt would see less immediate dilution advantage if talent levels remain strong.
-105.20%
Both reduce yoy usage, with AVGO at -24.30%. Martin Whitman would find an industry or cyclical factor prompting leaner operational approaches.
-3.33%
Both yoy AR lines negative, with AVGO at -164.27%. Martin Whitman would suspect an overall sector lean approach or softer demand.
-72.20%
Negative yoy inventory while AVGO is 48.82%. Joel Greenblatt would see a near-term cash advantage if top-line doesn't suffer.
-19.05%
Negative yoy AP while AVGO is 186.36%. Joel Greenblatt would see quicker payments or less reliance on trade credit than competitor, unless expansions are hindered.
-11.29%
Both reduce yoy usage, with AVGO at -140.15%. Martin Whitman would suspect an industry or cyclical factor pulling back on these items.
-117.24%
Negative yoy while AVGO is 6.78%. Joel Greenblatt would see a near-term net income or CFO stability advantage unless competitor invests or writes down more aggressively.
-26.17%
Negative yoy CFO while AVGO is 3.59%. Joel Greenblatt would see a disadvantage in operational cash generation vs. competitor.
-22.41%
Both yoy lines negative, with AVGO at -5.17%. Martin Whitman would suspect a cyclical or broad capital spending slowdown in the niche.
No Data
No Data available this quarter, please select a different quarter.
15.14%
Less growth in investment purchases vs. AVGO's 100.00%, preserving near-term liquidity. David Dodd would confirm no strategic investment opportunities are lost.
20.34%
We have some liquidation growth while AVGO is negative at -100.00%. John Neff notes a short-term liquidity advantage if competitor is holding or restricted.
-120.00%
Both yoy lines negative, with AVGO at -99.50%. Martin Whitman suspects a cyclical or strategic rationale for cutting extra invests in the niche.
51.40%
We have mild expansions while AVGO is negative at -260.00%. John Neff sees competitor possibly divesting or pausing expansions more aggressively.
214.96%
Debt repayment growth of 214.96% while AVGO is zero at 0.00%. Bruce Berkowitz sees a mild advantage that can reduce interest costs unless expansions demand capital here.
-35.90%
Negative yoy issuance while AVGO is 0.00%. Joel Greenblatt sees a near-term advantage in avoiding dilution unless competitor invests more effectively with the new shares.
14.86%
Buyback growth below 50% of AVGO's 84.71%. Michael Burry suspects fewer capital returns to shareholders vs. competitor, unless expansions hold higher ROI.